Replies to post #165851 on Anavex Life Sciences Corp (AVXL)

[falconer66a]

Anavex Therapies Will Be Expansive

If I remember correctly, the MB raised the idea of 2-73/3-71 possibly helping with the CTE injuries about two years ago with several folks contacting IR about the idea. Nothing has ever come of it, at least, publicly.

The presumption that, if at all possible, Anavex molecules might be therapeutic for just a handful of specific central nervous system diseases most likely will turn out to be very wrong. Presently, three CNS conditions are targeted: Alzheimer’s, Parkinson’s, and Rett syndrome. Very well.

Understand, of course, that the Anavex sigma-1 receptor agonists favorably resolve mitochondrial deficiencies in CNS diseases. Alzheimer’s and Parkinson’s are not the only diseases caused by or involved with mitochondrial dysfunction. There are a host of such diseases and conditions; any of which may eventually be resolved by Anavex molecules.

Many others are caused by improperly-folded proteins, distorted enzymes that cannot properly mediate chemical reactions. Facilitate full endoplasmic reticular function (the folding of proteins), and cellular biochemistry is normalized.

Doctor Missling’s “tip of the iceberg” tangential reference to potential Anavex applications was not merely a flippant turn of phrase. He and his scientific advisors know the wide scope of potential Anavex therapies. They extend far beyond a few CNS diseases. Mitochondrial dysfunction and incomplete protein folding are core etiologies for a host of human diseases. With its several proprietary molecules (beyond Anavex 2-73), the company has the potential of treating an expanded variety of diseases and conditions. From murine tests, insiders know of these, the iceberg phenomenon. In time, the rest of the world will know, and benefit.